We’re looking for people to help shape our submission to NICE’s appraisal for ribociclib with an aromatase inhibitor for adjuvant treatment of hormone-receptor-positive, HER2-negative early breast cancer

Going through breast cancer treatment Chemotherapy
1

Hi all,

My name is Abi, I work with the Policy, Evidence and Influencing team at Breast Cancer Now. We are looking for people to help shape our input into the National Institute for Healthcare Excellence’s (NICE) appraisal into ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor positive, HER2-negative primary breast cancer for use on the NHS. Adjuvant therapies are treatments given after surgery.

Ribociclib is already used for some secondary, or metastatic, breast cancer patients. NICE are assessing the effectiveness of adjuvant ribociclib for treating hormone receptor positive HER2-negative primary breast cancer.

We’re looking to hear from people who have experience of this treatment for primary breast cancer, for example you may have received the treatment through the clinical trial. By sharing your experience of the treatment you’ll help to shape our input into NICE’s appraisal. We’re also looking for people who might benefit from this treatment if it were to be approved for use on the NHS. Anything shared will be kept anonymous.

If you’d be happy to share your experience, please email policy@breastcancernow.org by 5pm Monday 14th October.

Thank you!

2

Hi all,

I just wanted to follow up to ask if anyone would still be able to support us with the appraisal.

We would be keen to hear from someone who has used ribociclib, or from someone who might benefit from its use if it was to be approved.

If you would be able to help, please email policy@breastcancernow.org by Wednesday 23rd October and will aim to pencil in a catch up with you.

Thank you,

Abi

1 Like